Mithramycin targets head and neck cancer stem cells by inhibiting Sp1 and UFMylation
Abstract Background The development of resistance to therapy is characteristic of head and neck squamous cell carcinoma (HNSCC), the 6th most common cancer, and is often attributed to cancer stem cells (CSCs). By proteomic approach, we determined that UFMylation plays an important role in HNSCC CSCs...
Saved in:
| Main Authors: | Kristina Vukovic Derfi, Tea Vasiljevic, Tea Dragicevic, Tanja Matijevic Glavan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03609-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical Pharmacokinetic Evaluation of Mithramycin and Mithramycin SA Tryptophan-Conjugated Analog
by: Kumar Kulldeep Niloy, et al.
Published: (2025-06-01) -
Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor
by: Maggie H Chasse, et al.
Published: (2020-12-01) -
The UFMylation pathway is impaired in Alzheimer’s disease
by: Tingxiang Yan, et al.
Published: (2024-12-01) -
UFMylation of NLRP3 Prevents Its Autophagic Degradation and Facilitates Inflammasome Activation
by: Jiongjie Jing, et al.
Published: (2025-04-01) -
Comparative proteomics reveals a diagnostic signature for pulmonary head‐and‐neck cancer metastasis
by: Hanibal Bohnenberger, et al.
Published: (2018-08-01)